

Understanding LEQEMBI[®] Dosing Options

Initiation: First 18 Months*

LEQEMBI IQLIK[®]



Once-weekly at-home subcutaneous injection

500 mg — Two 250 mg single-dose prefilled autoinjectors, administered sequentially

LEQEMBI IQLIK[®]



Maintenance: Consider After 18 Months*

LEQEMBI IQLIK[®]



Once-weekly at-home subcutaneous injection

360 mg — One single-dose prefilled autoinjector

LEQEMBI is also available via infusion*



Infusion once every 2 weeks for the first 18 months

Twice-monthly infusions — recommended starting dosage is 10 mg/kg over approximately 1 hour



Infusion once every 4 weeks after the first 18 months

Patients have the option to transition to once-monthly infusion

For information on switching or transitioning between LEQEMBI IQLIK and infusion administration, refer to the full Prescribing Information



Obtain a recent baseline brain MRI prior to initiating treatment and after month 1, 2, 3, and 6 of treatment. In general, the MRI should be performed within approximately one week before the next scheduled infusion or injection of LEQEMBI and reviewed prior to proceeding with the infusion or injection. MRI timing is the same for both LEQEMBI IQLIK and infusion, but corresponds to different dose numbers due to route-specific dosage cadence (e.g., prior to the 3rd dose for the intravenous route or 5th dose for the subcutaneous route).

Throughout treatment, if a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including an MRI if indicated.

*Please see Instructions for Use with the Prescribing Information

IMPORTANT SAFETY INFORMATION

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease, which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

What is the most important information I should know about LEQEMBI?

LEQEMBI can cause serious side effects, including: ARIA (Amyloid-Related Imaging Abnormalities). ARIA is a side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.

- ARIA commonly shows up as temporary swelling in areas of the brain that usually goes away over time
- Small spots of bleeding in or on the surface of the brain can occur
- Less often, larger areas of bleeding in the brain can occur
- Most people with ARIA don’t have any symptoms. However, some people may notice:

- | | | |
|-------------|----------------------|-----------------------|
| – headache | – vision changes | – seizures |
| – confusion | – nausea | – difficulty speaking |
| – dizziness | – difficulty walking | – muscle weakness |

 Some people have a gene called ApoE4 that may increase the risk of ARIA. Talk to your healthcare provider about testing to see if you have this gene

 Your healthcare provider will check for ARIA with MRI (magnetic resonance imaging) scans before you start LEQEMBI and during treatment

 You may be at a higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving LEQEMBI. Talk to your healthcare provider to see if any of the medicines you’re taking increase this risk

 You should carry information that says you are receiving LEQEMBI, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms

 **Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above.**

 **Serious allergic reactions:**
Do not receive LEQEMBI if you have serious allergic reactions to LEQEMBI, LEQEMBI IQLIK, or any of the ingredients.

- Tell your healthcare provider and get medical help right away if you notice any symptoms during or after treatment with LEQEMBI, including:

- | | | |
|--|--|------------------------|
| – swelling of the face, lips, mouth, or tongue | – itchy bumps on the skin, also known as hives | – difficulty breathing |
|--|--|------------------------|

Infusion-related reactions:

- Infusion-related reactions are a common side effect that can occur during or after completion with LEQEMBI injection into a vein (intravenously), which can be serious. Tell your healthcare provider right away if you notice any of these symptoms:

- | | | |
|---|---|---|
| – fever | – dizziness or lightheadedness | – difficulty breathing or shortness of breath |
| – flu-like symptoms (chills, body aches, feeling shaky, joint pain) | – fast or slow heart rate, or feeling like your chest is pounding | – changes in blood pressure |
| – nausea and/or vomiting | | |

- If you have an infusion-related reaction, your healthcare provider may give you medicines before your next infusion to lower the chance of having a reaction.

Injection-related reactions:

- Injection-related reactions may occur with LEQEMBI injection under the skin (subcutaneous injection with LEQEMBI IQLIK). Tell your healthcare provider if you notice any of these symptoms during or after an injection:

- | | |
|---|---|
| – redness, swelling, heat, pain, itching, rash, bump, bruising, and blood collection under the skin at the injection site | – headache, chills, fatigue, or fever may also be observed after an injection |
|---|---|

 **The most common side effects** of LEQEMBI include infusion-related reactions with LEQEMBI injected into a vein, ARIA, and headache.

 **These are not all the possible side effects of LEQEMBI. Call your doctor for more information and medical advice about side effects. You may report side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.**

 **Before receiving LEQEMBI, tell your healthcare provider about:**

- **All your medical conditions**, including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if LEQEMBI could harm your unborn or breastfeeding baby
- **All the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin)

LEQEMBI (lecanemab-irmb) is available as:

- Intravenous infusion: 100 mg/mL
- Subcutaneous injection: 200 mg/mL

Please see Medication Guide with Instructions for Use and full Prescribing Information, including Boxed WARNING, for LEQEMBI on LEQEMBI.com.